



# Diagnostics

- October 2023 -

# Diagnostics Funding - October 2023 By Amount Raised

## The category accounted for \$116.5 Million of Deals, Across 5 Deals

Date	Company	Investment Cluster	About	Investment (\$M)	Round	Investors
10-05	Precede Biosciences	Boston	Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw.	\$57.00	Series A	5AM Ventures (Lead), Lilly Asia Ventures (Lead), OUP, BMS, Qatar Investment Authority, Binnery Street Capital,
10-18	4D Lifetec	Europe	4D Lifetec is a biotechnology company promoting and developing screening and test systems for molecular diagnostics.	\$26.00	Series C	Xlife Sciences AG
10-11	AOA Dx	Colorado	AOA Dx is a biotech company developing cancer diagnostics in the field of women's health.	\$17.00	Venture	Good Growth Capital, Y Combinator, VU Venture, The Helm, RH Capital, LongeVC, LabCorp Venture Fund, Gore Range, FemHealth, Cancer Fund
10-31	Aqtual	San Francisco	Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics by analyzing previously unexplored cell-free DNA fragments found in blood.	\$16.00	Series A	co-led by Genoa Ventures, Manta Ray Ventures, and Yu Galaxy.
10-19	Mestastop Solutions	Asia	Proprietary in vitro, in vivo and patient ex-vivo platforms to address cancer metastasis drug discovery and predictive diagnostics	\$0.54	Seed	92 Angels, Malpani Ventures